TABLE 4.
Antimicrobial resistance by serogroup and serotype of NTS bloodstream isolates submitted to NARMS, 1996 to 2007
| Salmonella serogroup | Salmonella serotype (no. of isolates) | No. (%) of isolates by antimicrobial resistance patternd |
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMC | AMP | CEP | CHL | CIP | CRO | FOXa | GEN | NAL | SSSb | SXT | TET | Fully susceptible | ≥1 agent | Clinically important | R-type ACSSuT | ||
| O:4 (B) | Agona (12) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 6 (50.0) | 0 (0.0) | 6 (50.0) | 6 (50.0) | 6 (50.0) | 0 (0.0) | 0 (0.0) |
| 1,4,[5],12:i− (18) | 0 (0.0) | 1 (5.6) | 0 (0.0) | 1 (5.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (5.6) | 0 (0.0) | 1 (5.6) | 17 (94.4) | 1 (5.6) | 1 (5.6) | 1 (5.6) | |
| Heidelberg (141) | 6 (4.3) | 24 (17.0) | 5 (3.6) | 1 (0.7) | 0 (0.0) | 6 (4.3) | 5 (3.6) | 16 (11.4) | 0 (0.0) | 19 (13.5) | 0 (0.0) | 18 (12.8) | 98 (69.5) | 43 (30.5) | 34 (24.1) | 1 (0.7) | |
| Saintpaul (17) | 1 (5.9) | 1 (5.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (5.9) | 1 (5.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 4 (23.5) | 13 (76.5) | 4 (23.5) | 1 (5.9) | 0 (0.0) | |
| Sandiego (19) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (5.3) | 0 (0.0) | 0 (0.0) | 17 (89.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) | |
| Schwarzengrund (10) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (20.0) | 0 (0.0) | 2 (20.0) | 8 (80.0) | 2 (20.0) | 0 (0.0) | 0 (0.0) | |
| Typhimurium (210) | 6 (2.9) | 116 (55.2) | 3 (1.4) | 88 (41.9) | 0 (0.0) | 4 (1.9) | 4 (1.9) | 4 (1.9) | 2 (1.0) | 127 (60.5) | 11 (5.2) | 110 (52.4) | 77 (36.7) | 133 (63.3) | 119 (56.7) | 82 (39.1) | |
| Other (30) | 1 (3.3) | 5 (16.7) | 2 (6.7) | 1 (3.3) | 0 (0.0) | 1 (3.3) | 1 (3.3) | 1 (3.3) | 1 (3.3) | 3 (10.0) | 1 (3.3) | 7 (23.3) | 20 (66.7) | 10 (33.3) | 5 (16.7) | 1 (3.3) | |
| Total (457) | 14 (3.1) | 147 (32.2) | 10 (2.2) | 91 (19.9) | 0 (0.0) | 12 (2.6) | 11 (2.4) | 21 (4.6) | 3 (0.7) | 159 (34.8) | 12 (2.6) | 148 (32.4) | 256 (56.0) | 201 (44.0) | 160 (35.0) | 85 (18.6) | |
| O:7 (C1) | Infantis (10) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 10 (100.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Montevideo (22) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (4.6) | 0 (0.0) | 1 (4.6) | 0 (0.0) | 1 (4.6) | 21 (95.5) | 1 (4.6) | 1 (4.6) | 0 (0.0) | |
| Oranienburg (39) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.6) | 0 (0.0) | 2 (5.1) | 0 (0.0) | 0 (0.0) | 36 (92.3) | 3 (7.7) | 1 (2.6) | 0 (0.0) | |
| Other (46) | 0 (0.0) | 5 (10.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (4.4) | 8 (17.4) | 16 (34.8) | 7 (15.2) | 12 (26.1) | 27 (58.7) | 19 (41.3) | 10 (21.7) | 0 (0.0) | |
| Total (117) | 0 (0.0) | 5 (4.3) | 0 (0.0) | 1 (0.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 4 (3.4) | 8 (6.8) | 20 (16.2) | 7 (6.0) | 13 (11.1) | 94 (80.3) | 23 (19.7) | 12 (10.3) | 0 (0.0) | |
| O:8 (C2-C3) | Newport (35) | 7 (20.0) | 8 (22.9) | 6 (17.1) | 9 (25.7) | 0 (0.0) | 7 (20.0) | 7 (20.0) | 1 (2.9) | 0 (0.0) | 10 (28.6) | 1 (2.9) | 10 (28.6) | 25 (71.4) | 10 (28.6) | 8 (22.9) | 7 (20.0) |
| Other (19) | 0 (0.0) | 1 (5.3) | 1 (5.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (10.5) | 1 (5.3) | 5 (26.3) | 13 (68.4) | 6 (31.6) | 2 (10.5) | 0 (0.0) | |
| Total (54) | 7 (13.0) | 9 (16.7) | 7 (13.0) | 9 (16.7) | 0 (0.0) | 7 (13.0) | 7 (13.0) | 1 (1.9) | 0 (0.0) | 12 (22.2) | 2 (3.7) | 15 (27.8) | 38 (70.4) | 16 (29.6) | 10 (18.5) | 7 (13.0) | |
| O:9 (D1) | Dublin (39) | 4 (10.3) | 13 (33.3) | 1 (2.6) | 13 (33.3) | 0 (0.0) | 4 (10.3) | 4 (10.3) | 1 (2.6) | 2 (5.1) | 16 (41.0) | 0 (0.0) | 15 (38.5) | 23 (59.0) | 16 (41.0) | 13 (33.3) | 10 (25.6) |
| Enteritidis (232) | 2 (0.9) | 27 (11.6) | 2 (0.9) | 1 (0.4) | 0 (0.0) | 2 (0.9) | 2 (0.9) | 1 (0.4) | 13 (5.6) | 8 (3.5) | 4 (1.7) | 14 (6.0) | 188 (81.0) | 44 (19.0) | 29 (12.5) | 1 (0.4) | |
| Javiana (14) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (7.1) | 0 (0.0) | 0 (0.0) | 1 (7.1) | 12 (85.7) | 2 (14.3) | 0 (0.0) | 0 (0.0) | |
| Panama (12) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (8.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (8.3) | 11 (91.7) | 1 (8.3) | 0 (0.0) | 0 (0.0) | |
| Other (14) | 0 (0.0) | 3 (21.4) | 0 (0.0) | 1 (7.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (21.4) | 1 (7.1) | 4 (28.6) | 0 (0.0) | 1 (7.1) | 8 (57.1) | 6 (42.9) | 5 (35.7) | 1 (7.1) | |
| Total (311) | 6 (1.9) | 43 (13.8) | 3 (1.0) | 16 (5.1) | 0 (0.0) | 6 (1.9) | 6 (1.9) | 5 (1.6) | 17 (5.5) | 28 (9.0) | 4 (1.3) | 32 (10.3) | 242 (77.8) | 69 (22.1) | 47 (15.1) | 12 (5.9) | |
| O:3,10 (E1) | Total (19) | 0 (0.0) | 1 (5.3) | 1 (5.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (5.3) | 0 (0.0) | 1 (5.3) | 0 (0.0) | 1 (5.3) | 18 (94.7) | 1 (5.3) | 1 (5.3) | 0 (0.0) |
| O:1,3,19 (E4) | Total (1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| O:11 (F) | Total (8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (12.5) | 0 (0.0) | 1 (12.5) | 0 (0.0) | 0 (0.0) | 7 (87.5) | 1 (12.5) | 1 (12.5) | 0 (0.0) |
| O:13 (G) | Poona (13) | 0 (0.0) | 1 (7.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (7.7) | 12 (92.3) | 1 (7.7) | 1 (7.7) | 0 (0.0) |
| Other (20) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (10.0) | 18 (90.0) | 2 (10.0) | 0 (0.0) | 0 (0.0) | |
| Total (33) | 0 (0.0) | 1 (3.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (9.1) | 30 (90.9) | 3 (9.1) | 1 (3.0) | 0 (0.0) | |
| Othersc | Total (50) | 1 (2.0) | 2 (4.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.0) | 1 (2.0) | 1 (2.0) | 0 (0.0) | 3 (6.0) | 1 (2.0) | 2 (4.0) | 44 (88.0) | 6 (12.0) | 3 (6.0) | 0 (0.0) |
| All | Total (1,050) | 28 (2.7) | 208 (19.8) | 21 (2.0) | 117 (11.1) | 0 (0.0) | 26 (2.5) | 25 (2.4) | 34 (3.2) | 28 (2.7) | 223 (21.2) | 26 (2.5) | 214 (20.4) | 730 (69.5) | 320 (30.5) | 235 (22.4) | 104 (9.9) |
a
Cefoxitin testing began in 2000.
b
For sulfonamide resistance, sulfamethoxazole was tested from 1996 through 2003, and sulfisoxazole was tested from 2004 through 2007.
c
Includes serogroups O:6,14 (H) (1 isolate), O16 (I) (2 isolates), O:18 (K) (2 isolates), O:28 (M) (9 isolates), O:30 (N) (3 isolates), O:35 (O) (3 isolates), and O:40 (R) (2 isolates).
d
Antimicrobial agents: AMC, amoxicillin-clavulanate; AMP, ampicillin; CEP, cephalothin; CHL, chloramphenicol; CIP, ciprofloxacin; CRO, ceftriaxone; FOX, cefoxitin; GEN, gentamicin; NAL, naldixic acid; SSS, sulfonamides; SXT, trimethoprim-sulfamethoxazole; TET, tetracycline. Fully susceptible, susceptible to all antimicrobial agents tested in NARMS panel; ≥1 agent, resistant to one or more antimicrobial agent in NARMS panel; clinically important, resistant to ampicillin, ceftriaxone, ciprofloxacin, gentamicin, and/or trimethoprim-sulfamethoxazole; ACSSuT, resistant to at least ampicillin, chloramphenicol, streptomycin, sulfonamide, and tetracycline.